Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen T Durant

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|December 8, 2005
The SET domain protein Metnase mediates foreign DNA integration and links integration to nonhomologous end-joining repairSuk-Hee Lee, Masahiko Oshige, Stephen T Durant, et al.
Plos One|December 20, 2012
Structures of the human poly (ADP-ribose) glycohydrolase catalytic domain confirm catalytic mechanism and explain inhibition by ADP-HPD derivativesJulie A Tucker, Neil Bennett, Claire Brassington, et al.
Nucleic Acids Research|May 12, 2010
Metnase promotes restart and repair of stalled and collapsed replication forksLeyma P De Haro, Justin Wray, Elizabeth A Williamson, et al.
British Journal of Cancer|August 4, 2020
Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer modelsCharles R Dunlop, Yann Wallez, Timothy Isaac Johnson, et al.
Oncogene|February 14, 2003
Interactions of the DNA mismatch repair proteins MLH1 and MSH2 with c-MYC and MAXMary Mac Partlin, Elizabeth Homer, Helen Robinson, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 1, 2023
CRISPR metabolic screen identifies ATM and KEAP1 as targetable genetic vulnerabilities in solid tumorsHaojian Li, Yue Liu, Yunjie Xiao, et al.
Science Translational Medicine|August 19, 2021
ALT neuroblastoma chemoresistance due to telomere dysfunction-induced ATM activation is reversible with ATM inhibitor AZD0156Balakrishna Koneru, Ahsan Farooqi, Thinh H Nguyen, et al.
Nature Chemical Biology|August 16, 2016
Cellularly active N-hydroxyurea FEN1 inhibitors block substrate entry to the active siteJack C Exell, Mark J Thompson, L David Finger, et al.
BMC Cancer|October 30, 2022
ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancerS Lindsey Davis, Sarah J Hartman, Stacey M Bagby, et al.
Nature Communications|January 10, 2019
ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forksGabriel Balmus, Domenic Pilger, Julia Coates, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Proceedings of the National Academy of Sciences of the United States of America|December 8, 2005
The SET domain protein Metnase mediates foreign DNA integration and links integration to nonhomologous end-joining repairSuk-Hee Lee, Masahiko Oshige, Stephen T Durant, et al.
Plos One|December 20, 2012
Structures of the human poly (ADP-ribose) glycohydrolase catalytic domain confirm catalytic mechanism and explain inhibition by ADP-HPD derivativesJulie A Tucker, Neil Bennett, Claire Brassington, et al.
Nucleic Acids Research|May 12, 2010
Metnase promotes restart and repair of stalled and collapsed replication forksLeyma P De Haro, Justin Wray, Elizabeth A Williamson, et al.
British Journal of Cancer|August 4, 2020
Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer modelsCharles R Dunlop, Yann Wallez, Timothy Isaac Johnson, et al.
Oncogene|February 14, 2003
Interactions of the DNA mismatch repair proteins MLH1 and MSH2 with c-MYC and MAXMary Mac Partlin, Elizabeth Homer, Helen Robinson, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 1, 2023
CRISPR metabolic screen identifies ATM and KEAP1 as targetable genetic vulnerabilities in solid tumorsHaojian Li, Yue Liu, Yunjie Xiao, et al.
Science Translational Medicine|August 19, 2021
ALT neuroblastoma chemoresistance due to telomere dysfunction-induced ATM activation is reversible with ATM inhibitor AZD0156Balakrishna Koneru, Ahsan Farooqi, Thinh H Nguyen, et al.
Nature Chemical Biology|August 16, 2016
Cellularly active N-hydroxyurea FEN1 inhibitors block substrate entry to the active siteJack C Exell, Mark J Thompson, L David Finger, et al.
BMC Cancer|October 30, 2022
ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancerS Lindsey Davis, Sarah J Hartman, Stacey M Bagby, et al.
Nature Communications|January 10, 2019
ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forksGabriel Balmus, Domenic Pilger, Julia Coates, et al.
Pageof 3